Neuropeptide Y (NPY) Receptor Modulators in Neurodegeneration

📖 Wiki Page

therapeutic1774 wordssynced 2026-04-02

Neuropeptide Y (NPY) Receptor Modulators in Neurodegeneration

...

Neuropeptide Y (NPY) Receptor Modulators in Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Neuropeptide Y (NPY) Receptor Modulators in Neurodegeneration</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Receptor</td>
</tr>
<tr>
<td class="label">[NPY (1-36) analogue](/peptides/npy-analogue)</td>
<td>Y1/Y2 pan-agonist</td>
</tr>
<tr>
<td class="label">BIIE0246 derivative</td>
<td>Y2 antagonist</td>
</tr>
<tr>
<td class="label">[PF-05047771](/companies/pfizer)</td>
<td>Y1 agonist</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Receptor</td>
</tr>
<tr>
<td class="label">J-215381</td>
<td>Y2 antagonist</td>
</tr>
<tr>
<td class="label">[BIIE0246](/compounds/biie0246)</td>
<td>Y2 antagonist</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Sponsor</td>
</tr>
<tr>
<td class="label">NPY-GT-001</td>
<td>NeuroGene Inc.</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">[SAR-127899](https://pubmed.ncbi.nlm.nih.gov/24928594/)</td>
<td>Obesity/metabolic</td>
</tr>
<tr>
<td class="label">[PF-04647603](https://pubmed.ncbi.nlm.nih.gov/31354290/)</td>
<td>Binge eating</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">PF-05047771</td>
<td>Pfizer</td>
</tr>
<tr>
<td class="label">SAR-127899</td>
<td>Sanofi</td>
</tr>
<tr>
<td class="label">NPY-GT-001</td>
<td>NeuroGene Inc.</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Method</td>
</tr>
<tr>
<td class="label">CSF NPY</td>
<td>Lumipulse/EIA</td>
</tr>
<tr>
<td class="label">Y1R binding</td>
<td>PET ligands</td>
</tr>
<tr>
<td class="label">Neurogenesis</td>
<td>CSF NfL, BDNF</td>
</tr>
<tr>
<td class="label">Stress markers</td>
<td>Cortisol, CRF</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Y1 agonist</td>
<td>PD (dopamine protection)</td>
</tr>
<tr>
<td class="label">Y2 antagonist</td>
<td>AD (memory, neurogenesis)</td>
</tr>
<tr>
<td class="label">Y5 antagonist</td>
<td>HD (metabolic dysfunction)</td>
</tr>
</table>

Overview

Neuropeptide Y (NPY) is a 36-amino acid peptide abundantly expressed in the central nervous system, particularly in the [hypothalamus](/brain-regions/hypothalamus), [amygdala](/brain-regions/amygdala), hippocampus, and locus coeruleus. NPY signals through four G-protein-coupled receptors (Y1, Y2, Y4, Y5), with Y1 and Y2 being the most relevant for neurodegenerative disease therapeutics[@npy_alzheimer].

NPY serves as a powerful endogenous neuroprotective system with four key actions relevant to neurodegeneration:

Anxiolytic and anti-stress: NPY counters the HPA-axis activation and CRF-mediated toxicity that accelerates neurodegeneration

Promotes neurogenesis: Particularly in the hippocampal dentate gyrus, protecting memory circuits

Inhibits glutamate excitotoxicity: Via presynaptic Y2 receptor modulation of neurotransmitter release

Modulates neuroinflammation: Reduces microglial activation and inflammatory cytokine release

NPY System in Alzheimer's Disease

In AD, NPY expression is significantly reduced in the hippocampus and cortex[@npy_alzheimer]. This reduction correlates with:

Memory impairment: NPY-deficient mice show impaired spatial memory and LTP deficits
Tau pathology: NPY-Y1R signaling normally suppresses GSK-3β activity; loss of NPY disinhibits tau phosphorylation[@npy_tau]
Aβ toxicity: NPY protects against oligomeric Aβ-induced synaptic toxicity and neuronal death

Y1 Receptor Agonists in AD

Y1R activation is neuroprotective through multiple pathways[@y1_agonist_neurprotection]:

Activates PLC-PKC signaling cascade → promotes neuronal survival
Inhibits N-type calcium channels → reduces excitotoxic calcium influx
Upregulates BDNF expression → supports hippocampal neurogenesis
Suppresses neuroinflammation via NF-κB inhibition

Therapeutic candidates:

Y2 Receptor Antagonists in AD

Y2 receptors are primarily presynaptic; antagonists increase NPY release and are pro-cognitive[@y2_antagonist_memory]:

Block presynaptic Y2 autoinhibition → ↑ NPY and GABA release
Enhance hippocampal neurogenesis (15-20% increase in dentate gyrus)
Improve memory consolidation in AD mouse models
Reduce amyloid burden via autophagy enhancement

Research compounds:

NPY System in Parkinson's Disease

In PD, NPY neurons in the [substantia nigra](/brain-regions/substantia-nigra) and striatum progressively degenerate, contributing to both motor and non-motor symptoms[@npy_parkinson]. NPY provides critical protection to dopaminergic neurons:

Dopamine neuron survival: NPY-Y1R activation promotes survival of [ventral tegmental area](/brain-regions/ventral-tegmental-area) and substantia nigra pars compacta neurons
Alpha-synuclein toxicity: NPY directly counteracts α-synuclein oligomer formation and protects against oxidative stress[@npy_synuclein]
Neuroinflammation: Y2 receptor activation on microglia reduces M1 pro-inflammatory phenotype

Y1 Agonists in PD

BMS-983324 is a selective, brain-penetrant Y1 agonist that has shown promise in PD models[@bms983324]:

Dopamine neuron protection: 40% reduction in MPTP-induced dopaminergic cell death
Behavioral benefit: Improved locomotor activity in 6-OHDA lesioned rats
Synuclein interaction: Reduces α-synuclein aggregation via Y1R-mediated autophagy enhancement

Development status: Preclinical. No Y1 agonist has advanced to clinical trials for PD as of 2026.

NPY Gene Therapy for PD

AAV-mediated NPY overexpression represents a disease-modifying approach:

Approach: Deliver human NPY under control of a neuronal promoter via AAV9
Evidence: Intranigral AAV-NPY in MPTP mice preserved TH+ neurons (67% vs 23% in controls)
Advantage: Long-term expression from single injection; addresses progressive NPY loss
Challenge: Requires direct brain injection (stereotactic)

NPY System in Amyotrophic Lateral Sclerosis

NPY expression is upregulated in ALS motor neurons as a compensatory neuroprotective response[@npy_als]. However, this endogenous protection is insufficient:

Motor neuron vulnerability: Y2R expression on motor neurons decreases in ALS, reducing NPY's protective effect
Neuroinflammation: NPY-Y2R signaling normally suppresses microglial activation; this is lost in ALS
Excitotoxicity: NPY normally inhibits glutamate release via Y2; loss of this function contributes to excitotoxic death

Therapeutic Strategies in ALS

Y2 receptor agonists: Activate remaining Y2 receptors on motor neurons and glia

NPY analogues with enhanced stability: Pegylated or D-amino acid NPY with longer half-life

Y1/Y2 dual agonists: Maximize neuroprotection through both receptor subtypes

Research status: Very early-stage. No clinical programs for NPY-based ALS therapies as of 2026.

NPY System in Huntington's Disease

In HD, the NPY system is profoundly disrupted[@npy_huntington]:

Striatal NPY interneurons: These GABAergic neurons are relatively spared but their NPY content is reduced
HPA axis dysregulation: Elevated CRF and blunted NPY response contributes to psychiatric symptoms
Metabolic dysfunction: NPY normally regulates appetite and energy metabolism; loss contributes to cachexia

Y5 Receptor Antagonists

Y5 receptors are primarily orexigenic (appetite-stimulating). Y5 antagonists are in development for HD-related metabolic dysfunction:

HD application: Theoretical — Y5 antagonists could normalize appetite dysregulation in HD, but no dedicated HD program exists.

Cross-Disease Mechanisms

NPY receptor modulators share common mechanisms across neurodegenerative diseases:

1. Anti-Stress and HPA Axis Normalization

Chronic stress accelerates neurodegeneration via glucocorticoid toxicity, glutamate excitotoxicity, and neuroinflammation. NPY is the brain's primary anxiolytic peptide[@npy_stress_anxiety]:

Y1R activation in the amygdala reduces anxiety-like behavior
NPY counters CRF/urocortin toxicity in hippocampal neurons
Normalizes HPA axis feedback → reduces cortisol-mediated neurodegeneration

Implication: NPY-based therapies address the stress component common to AD, PD, and HD.

2. Neurogenesis Promotion

NPY-Y2 receptor activation stimulates hippocampal dentate gyrus neurogenesis:

Increases BrdU+ cell proliferation (2-3 fold increase)
Promotes survival of new neurons (40% improvement)
Enhances synaptic integration of new neurons
Improves pattern separation and memory encoding

Implication: NPY therapy could restore hippocampal plasticity lost in early AD and HD.

3. Excitotoxicity Protection

NPY-Y2 receptors are located presynaptically on glutamatergic terminals[@npy_alzheimer]:

Activation inhibits N-type (CaV2.2) calcium channels
Reduces glutamate release probability
Protects against kainic acid, NMDA, and AMPA excitotoxicity

Implication: Universal neuroprotective mechanism applicable across all neurodegenerative diseases.

4. Neuroinflammation Modulation

Microglial Y2 receptors regulate the M1/M2 phenotype balance:

Y2 activation shifts microglia toward M2 (neuroprotective) phenotype
Reduces IL-1β, TNF-α, and IL-6 release
Increases IL-10 and TGF-β secretion
Promotes phagocytosis of debris without excessive inflammation

Implication: Addresses the neuroinflammation common to all neurodegenerative diseases.

Drug Development Landscape

Clinical Stage Programs

Preclinical Programs

Y1 agonists: Multiple academic groups, no company-backed program
Y2 antagonists: BIIE0246 and derivatives as cognitive enhancers
NPY stable analogues: Modified NPY (1-36) with extended half-life
Peptide-NPY conjugates: Cell-targeting NPY constructs

Challenges in NPY Drug Development

Peptide stability: NPY (36 aa) is rapidly degraded (t1/2 ~ 20 min in plasma)

Solution: D-amino acid substitutions, pegylation, stapled helices

2. Blood-brain barrier penetration: Peptides generally poor at BBB crossing

Solution: Intranasal delivery, Trojan horse conjugates, small molecule agonists

3. Receptor selectivity: NPY receptors have overlapping ligand profiles

Solution: Structure-based drug design for subtype selectivity

4. Peripheral effects: Y receptors in gut, vasculature, and heart

Solution: Brain-restricted analogues, targeted CNS delivery

Biomarkers for NPY-Based Therapy

Monitoring NPY system engagement in clinical trials:

Therapeutic Approaches

1. Small Molecule Y1 Agonists

The most tractable approach for chronic oral dosing:

Requires high selectivity (avoid Y2/Y5 activation)
Must achieve adequate brain penetration (LogP 2-4)
Minimal off-target GPCR activity

Lead candidates: Research stage only. No company has disclosed clinical candidates.

2. Peptide NPY Analogues

Better receptor engagement but delivery challenges:

Modified NPY (1-36): D-amino acids at cleavage sites, enhanced stability
Stapled NPY peptides: Helical stabilizers improve resistance to proteolysis
Intranasal formulation: Bypasses BBB for direct brain delivery

Lead candidates: Academic programs only (Mayo Clinic, UCSF, UCSD).

3. Gene Therapy

Long-term expression from single injection:

AAV9-NPY for neuronal expression
Cell-type specific promoters (Synapsin, CamKIIa)
Addresses progressive NPY loss over time

Lead candidates: NeuroGene Inc. preclinical program.

4. Receptor-Selective Compounds

Targeting specific receptors for specific disease features:

Research Priorities

Develop Y1 agonist with adequate brain penetration — most critical for PD

Create stable NPY analogues for chronic dosing studies

PET ligands for Y1/Y2 receptors for target engagement biomarkers

Intranasal NPY delivery — immediate clinical translation path

Combination therapy: NPY + existing treatments (e.g., levodopa for PD, cholinesterase inhibitors for AD)

Conclusion

The NPY system represents a fundamentally neuroprotective pathway that is progressively lost across neurodegenerative diseases. Unlike disease-specific targets, NPY-Y1/Y2 receptor modulators address the convergent pathophysiology of stress-induced acceleration, excitotoxicity, neuroinflammation, and impaired neurogenesis.

The field awaits: (1) a brain-penetrant Y1 agonist with drug-like properties, (2) a stable NPY analogue suitable for chronic dosing, and (3) a Y2 antagonist with cognitive-enhancing effects. Gene therapy approaches offer the advantage of addressing progressive NPY loss with a single treatment.

Given the abundance of preclinical evidence and the endogenous neuroprotective role of NPY, this represents a high-priority therapeutic target for neurodegenerative disease modification.

References

[@npy_alzheimer] — NPY system overview in AD
[@npy_parkinson] — NPY alterations in PD
[@npy_als] — NPY in ALS
[@y1_agonist_neurprotection] — Y1R-mediated neuroprotection
[@y2_antagonist_memory] — Y2 antagonist cognitive enhancement
[@npy_tau] — NPY-Y1R modulation of tau phosphorylation
[@npy_synuclein] — NPY protection against α-synuclein toxicity
[@bms983324] — Y1 agonist in PD models
[@npy_huntington] — NPY system in HD
[@npy_stress_anxiety] — NPY and stress resilience

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄

📖 View canonical wiki page →

Neuropeptide Y (NPY) Receptor Modulators in Neurodegeneration

Neuropeptide Y (NPY) Receptor Modulators in Neurodegeneration

Neuropeptide Y (NPY) Receptor Modulators in Neurodegeneration

Overview

NPY System in Alzheimer's Disease

Y1 Receptor Agonists in AD

Y2 Receptor Antagonists in AD

NPY System in Parkinson's Disease

Y1 Agonists in PD

NPY Gene Therapy for PD

NPY System in Amyotrophic Lateral Sclerosis

Therapeutic Strategies in ALS

NPY System in Huntington's Disease

Y5 Receptor Antagonists

Cross-Disease Mechanisms

1. Anti-Stress and HPA Axis Normalization

2. Neurogenesis Promotion

3. Excitotoxicity Protection

4. Neuroinflammation Modulation

Drug Development Landscape

Clinical Stage Programs

Preclinical Programs

Challenges in NPY Drug Development

Biomarkers for NPY-Based Therapy

Therapeutic Approaches

1. Small Molecule Y1 Agonists

2. Peptide NPY Analogues

3. Gene Therapy

4. Receptor-Selective Compounds

Research Priorities

Conclusion

References

Related Hypotheses